CJ HealthCare’s ‘Anfrade’ exceeds KRW 20 billon prescriptions in market of its substance
The ‘Anfrade’ series, a CJ HealthCare’s line of chronic peripheral artery disease therapies, first passed KRW 20 billion sales in the market of the same substance.
CJ HealthCare announced on the 18th that its Anfrade series(Anfrade Tab 100mg, Anfrade SR Tab 300mg) recorded collective KRW 20.3 bi...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
